In a year that has already seen Connect Biopharma walk away from a Pfizer collaboration and halt its preclinical work, the biotech is now in the process of “significantly reducing” its presence in China.

The bacterium Clostridioides difficile is one of the most common infections picked up in hospitals, and, even once it’s cleared from the body, patients have a 1 in 6 chance of catching it again within a couple of months. It also often resists antibiotic treatment, leaving it free to infect the colon and cause diarrhea, nausea, fever and, in severe cases, sepsis and death.

Astellas Pharma has cut the ribbon on a new life sciences center in Massachusetts that will house 400 team members and an incubator lab.

With the rollout of its new over-the-counter continuous glucose monitor, Abbott aims to help its customers speak the hidden language of their bodies’ response to food, exercise and stress.

On the heels of an FDA rejection for its chief rival Novo Nordisk, Eli Lilly is gaining ground in the race to bring a once-weekly insulin to the U.S.

The bacterium Chlamydia trachomatis is best known for infecting genitals, causing the sexually transmitted infection (STI) known as chlamydia. But a new study has found that these sneaky cells can also infiltrate our guts, building a hidden supply of bacteria that could then leak to the genitals and cause reoccurring infections.

Parexel, a global contract research organization headquartered in Durham, North Carolina, is beefing up its ability to gather real-world data by bringing Mike D’Ambrosio on board as senior vice president and global head of real world research.

Abbott has launched a pivotal clinical trial to see if its deep-brain stimulation approach can make headway against treatment-resistant depression.

A new type of mpox, clade Ib, has been spreading rapidly within the Democratic Republic of Congo and leaking outside the African nation’s borders since Sept. 2023. In response, the World Health Organization (WHO) declared the outbreak a public health emergency of international concern (PHEIC) last month, the second such declaration for an mpox variant in the past two years.

Athira Pharma’s tumultuous journey to phase 2/3 Alzheimer’s disease data has ended in failure. The trial found fosgonimeton was no better than placebo on the primary and key secondary endpoints, driving investors to cut the cord holding up the biotech’s stock price.